Clinical Trials Logo
  1. Home
  2. Advanced/Metastatic Solid Tumors
  3. NCT04182516

Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors Clinical Trial

Official title:
A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors

Clinical Trial Summary

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04182516
Study type Interventional
Source Nerviano Medical Sciences
Contact
Status Active, not recruiting
Phase Phase 1
Start date November 25, 2019
Completion date December 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Active, not recruiting NCT04501276 - A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients Phase 1
Terminated NCT00996255 - Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors Phase 1
Terminated NCT02444793 - A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03526835 - A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05718895 - A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors Phase 1
Completed NCT03833427 - Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) Phase 1
Recruiting NCT04645069 - ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05607498 - First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma Phase 1
Recruiting NCT05405595 - ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02665416 - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors Phase 1
Terminated NCT01092052 - Study of NMS-1116354 in Advanced/Metastatic Solid Tumors Phase 1
Completed NCT05277402 - ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05614258 - Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05394168 - A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors Phase 1